CLAIMS:

1. The use, for the manufacture of a medicament for treating or preventing a disease associated with deposition of $A\beta$ in the brain, of a compound of Formula I

$$R^{4}$$
 R^{4}
 R^{2}
 R^{2}
 R^{2}
 R^{3}
 R^{2}
 R^{4}
 R^{5}
 R^{5}
 R^{1}
 R^{1}
 R^{1}
 R^{1}
 R^{2}
 R^{3}
 R^{2}
 R^{2}
 R^{3}
 R^{2}
 R^{3}
 R^{2}
 R^{3}
 R^{2}
 R^{3}
 R^{4}
 R^{5}
 R^{5}

5

10

15

20

wherein each R¹ is independently H, C₁₋₆alkyl or C₃₋₆cycloalkyl;

each R^2 is independently H or C_{1-6} alkyl, or the two R^2 groups together complete a C_{3-6} cycloalkyl group;

R³ represents a hydrocarbon group of up to 10 carbon atoms optionally bearing up to 2 substituents selected from halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy; or R³ represents a heteroaryl group of 5 or 6 ring atoms which is optionally benzo-fused, optionally bearing up to 2 substituents selected from C₁₋₄alkyl, halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy;

R⁴, R⁵ and R⁶ independently represent H, halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyloxy or hydrocarbon of up to 7 carbon atoms optionally bearing a substituent selected from halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy;

R⁷ represents a hydrocarbon group of up to 10 carbon atoms optionally bearing up to 2 substituents selected from halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy;

X represents O or S;

25

Y represents a bond, CH₂, CH₂CH₂, CH₂CH₂CH₂ or CH₂CH₂O; and Z represents CO₂H or tetrazol-5-yl; or a pharmaceutically acceptable salt thereof.

- 5 2. Use according to claim 1 wherein said disease is selected from Alzheimer's disease, cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia puglistica and Down syndrome.
- 3. Use, for the manufacture of a medicament for treating, preventing or delaying the onset of dementia associated with Alzheimer's disease, cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia pugilistica or Down syndrome, of a compound of Formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof.
- 4. Use, for the manufacture of a medicament for retarding, arresting or preventing the accumulation of Aβ in the brain, of a compound of Formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof.
- 5. Use according to any previous claim in which the medicament is for administration to a patient suffering from mild cognitive impairment or age related cognitive decline.
 - 6. Use according to any previous claim wherein X is S.
 - 7. Use according to any previous claim wherein Y is CH₂.
 - 8. Use according to any previous claim wherein Z is CO₂H.
- 9. Use according to any previous claim wherein R³ in formula I is selected from alkyl, cycloalkyl, alkyl-substituted phenyl and chloro-substituted phenyl.

- 10. Use according to any previous claim wherein R⁷ in formula I is selected from alkyl, cycloalkyl or alkenyl of up to 6 carbon atoms, or optionally substituted phenyl.
- 5 11. Use according to claim 1 of a compound according to formula II:

$$R^{4}$$
 X
 R^{3}
 R^{2}
 R^{2}
 R^{2}
 R^{2}
 R^{3}
 R^{2}
 R^{2}
 R^{3}
 R^{3}

wherein R^{1a} represents C_{1-6} alkyl or C_{3-6} cycloalkyl, and R^2-R^7 , X, Y and Z are as defined in claim 1;

- or a pharmaceutically acceptable salt thereof.
 - 12. Use according to claim 1 of a compound according to formula III:

$$R^{4}$$
 X
 R^{3}
 R^{2}
 R^{2}
 R^{5}
 R^{5}
 R^{1}
 R^{1}
 $(CF_{3})_{R}$

- wherein n is 1 or 2 and R¹-R⁶, X, Y and Z are as defined in claim 1; or a pharmaceutically acceptable salt thereof.
 - 13. A compound of formula II

5

10

$$\begin{array}{c|c}
R^4 & X & R^3 \\
X & R^2 & R^2 \\
Y & Z \\
\hline
R^6 & CH - R^{1a} \\
R^7 & (II)
\end{array}$$

wherein R^{1a} represents C₁₋₆alkyl or C₃₋₆cycloalkyl, and R²-R⁷, X, Y and Z are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

14. A compound of formula III:

$$\mathbb{R}^{4}$$
 \mathbb{R}^{2}
 \mathbb{R}^{2}
 \mathbb{R}^{2}
 \mathbb{R}^{2}
 \mathbb{R}^{2}
 \mathbb{R}^{2}
 \mathbb{R}^{2}
 \mathbb{R}^{3}
 \mathbb{R}^{2}
 \mathbb{R}^{2}
 \mathbb{R}^{3}
 \mathbb{R}^{2}
 \mathbb{R}^{3}
 \mathbb{R}^{2}
 \mathbb{R}^{3}
 \mathbb{R}^{2}
 \mathbb{R}^{3}
 \mathbb{R}^{3}
 \mathbb{R}^{2}
 \mathbb{R}^{3}
 \mathbb{R}^{3}
 \mathbb{R}^{3}
 \mathbb{R}^{3}
 \mathbb{R}^{2}
 \mathbb{R}^{3}
 \mathbb{R}^{3}

wherein n is 1 or 2 and R¹-R⁶, X, Y and Z are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, a compound of formula II or formula III, or a pharmaceutically acceptable salt thereof.